
Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2023 Apr 5)
ACS Chem Neurosci 14(7): 1291-1298
Baehr C, Kassick AJ, Vigliaturo J, Luengas D, Khaimraj A, Pravetoni M, Averick SE, Raleigh MD
(2023 May 1)
J Immunol 210(9): 1272-1280
Crouse B, Baehr C, Hicks D, Pravetoni M
(2023 Mar)
Expert Opin Investig Drugs 32(3): 181-185
Martinez S, Harris H, Chao T, Luba R, Pravetoni M, Comer SD, Jones JD
(2023 Jan 30)
Cell Rep 42(2): 112049
Triller G, Vlachou EP, Hashemi H, van Straaten M, Zeelen JP, Kelemen Y, Baehr C, Marker CL, Ruf S, Svirina A, Chandra M, Urban K, Gkeka A, Kruse S, Baumann A, Miller AK, Bartel M, Pravetoni M, Stebbins CE, Papavasiliou FN, Verdi JP
(2023 Jan)
Expert Opin Investig Drugs 32(1): 77-87
Luba R, Martinez S, Jones J, Pravetoni M, Comer SD
Show complete publication list »